|
Conference Reports, Abstracts, and Posters
|
Peg Interferon alfa-2a/Ribavirin |
Journal Papers, Abstracts, and Commentaries
| |
OPERA: use of pegylated interferon plus ribavirin for treating hepatitis
C/HIV co-infection in interferon-naive patients.
Carosi G, Bruno R, Cariti G, et al
Antivir Ther.
2014 Feb 28
Abstract
Addition of Nitazoxanide to PEG-IFN and Ribavirin to Improve HCV
Treatment Response in HIV-1 and HCV Genotype 1 Coinfected Persons Naïve
to HCV Therapy: Results of the ACTG A5269 Trial.
Amorosa VK, Luetkemeyer A, Kang M,
ry al
HIV Clin Trials. 2013
Nov-Dec;14(6):274-83
Abstract
The effects of a maintenance therapy with peg-interferon
alpha-2a on liver fibrosis in HIV/HCV co-infected patients: a randomized
controlled trial.
Chapplain JM, Bellissant E,
Guyader D, et al
J Infect.
2013 Jun 22
Abstract
Clinical evaluation of peginterferon α plus ribavirin for patients
co-infected with HIV and HCV at
Nagoya Medical Center.
Tsuzuki T, Iwase H, Shimada M, et
a;
Nihon Shokakibyo Gakkai Zasshi.
2012;109(7):1186-96.
Abstract
Effect of an induction period of pegylated interferon-α2a and ribavirin on
early virological response i
n HIV-HCV-coinfected patients: results from the CORAL-2 study.
Tural C, Solà R, Alvarez NP, et
al
Antivir Ther.
2011;16(6):833-841
Abstract
Effect of Baseline CD4 Cell Count on the Efficacy and Safety of
Peginterferon Alfa-2a (40KD)
Plus Ribavirin in Patients With HIV/Hepatitis C Virus Coinfection.
Opravil M, Sasadeusz J, Cooper DA, et al
J Acquir Immune Defic Syndr.
2008 Jan 1;47(1):36-49.
Abstract
|
|
Conference Reports, Abstracts, and Posters
| |
A WEEK-IN-REVIEW FEATURED REPORT
16 or 24 weeks of peginterferon alfa-2a (40kd) (pegasys®) plus
ribavirin (rbv) (copegus®) in
patients with hcv genotype 2 or 3 and bridging fibrosis or
cirrhosis: results from a large, randomised
multinational study (accelerate)
Zeuzem S., Pappas S., Nyberg L., et al
(12th International Symposium on Viral
Hepatitis and Liver
Disease)
Abstract
Baseline HCV Genotype 1 RNA Concentration: Relationships with Sustained
Virologic
Response to Peginterferon alfa-2a Plus Ribavirin and with Demographic
Characteristics
J. TICEHURST, J. RAKELA , H. BODENHEIMER, et
al
(45 ICAAC)
Abstract
|
Treatment Exposure and Sustained Virologic Response (SVR) in
Genotype 1 Patients Treated with
Peginterferon alfa-2a (40KD) (PEG IFNα2a)+ Ribavirin (RBV) in
APRICOT (AIDS PEGASYS Ribavirin
International Co-Infection Trial)
M. OPRAVIL, F. TORRIANI , J. SASADEUSZ, et al
(45 ICAAC)
Abstract
|
Determinants of Early Anti-HIV Effect of Pegylated
interferon alfa 2a (PegINF)
and Ribavirin (RBV) in Antiretroviral Therapy
(ART)-Free Coinfected HIV/HCV Patients
L.
VERONESE, D. AGUILAR, D. GONZALEZ DE REQUENA, et al
(45 ICAAC)
Abstract
|
Impact of Growth Factors (GF) on Treatment Outcomes in Patients with
HIV-HCV Co-Infection in
the AIDS PEGASYS Ribavirin (RBV) International Co-Infection Trial
(APRICOT)
M. SULKOWSKI, N. BRÄU , F. J. TORRIANI , et al
(45 ICAAC)
Abstract
|
|
|
| |
HCV-related factors but not HIV-related factors at baseline predict
the response to
treatment with peginterferon alfa-2a (40KD) (Pegasys) plus ribavirin (Copegus)
in patients
with HCV/HIV co-infection: Predictor analysis from the APRICOT study
D Cooper, FJ Torriani, M
Rodriguez-Torres, et al
(45th ICAAC)
Abstract
|
| |
Patients with HCV/HIV co-infection achieving a sustained virological
response following
HCV treatment with peginterferon alfa-2a (Pegasys®) plus
ribavirin (Copegus®) have improved
health related quality of life
DT Dieterich, M Rodriguez-Torres, JK Rockstroh, et al
(45th ICAAC)
Abstract
|
| |
Moderate dose of PegInterferon alfa-2b in combination with ribavirin
in the treatment of HCV
patients with or without HIV
C Sarmento, A Horta, H Coelho, O Vasconcelos, et al.
(45th ICAAC)
Abstract
|
| |
Safety of peginterferon alfa-2a (PEGASYS) 180 mcg weekly plus
ribavirin (RBV) 800 mg daily
in
HIV/HCV coinfection compared to HCV monoinfection
N Bräu, FJ Torriani, M Rodriguez-Torres, et al
(45th ICAAC)
Abstract
|
| |
Predictability of sustained virological response (SVR) in patients
with HCV/HIV co-infection during
combination therapy with peginterferon alfa-2A (40KD) (Pegasys®) plus
ribavirin (Copegus®) in the
APRICOT trial
M Rodriguez-Torres, FJ
Torriani, E Lissen, et al
(45th ICAAC)
Abstract
|
| |
PegInterferon-alfa2a plus ribavirin in HIV/HCV-coinfected patients:
early assessment of response in
the PRESCO trial
M Núñez, P Barreiro, A Ocampo.
et al
(45th
ICAAC)
Abstract |
|
|
Peg Interferon alfa-2a/Ribavirin
vs Interferon alfa-2a/Ribavirin
Journal Papers, Abstracts, and Commentaries
|
|
General
Reports
Peginterferon
Alfa-2a Main Page
Main
New/Newsworthy
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader